Predictors of mortality after transcatheter aortic valve implantation

Additionally, leukocyte, uric acid, CRP and CRP/albumin ratio were significantlyhigher and albumin was significantly lower in the deceased patients.Conclusion: The presence of chronic kidney disease, low left ventricular EF, high pulmonary artery pressure, high CRP levels, increasedCRP/albumin ratio and high uric acid levels preceding TAVI may be helpful to determine the risk of mortality after the TAVI procedure.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Aim: Transcatheter aortic valve implantation has been used widely as an alternative treatment method for patients with symptomaticaortic stenosis carrying high surgical risk.

📊

Key Findings & Data:Despite technological advances and increased experience, its early and late mortality rateis still relatively high and it is important to predict upcoming cardiac events and mortality for the management of patients.

💡

Conclusion & Impact:Additionally, leukocyte, uric acid, CRP and CRP/albumin ratio were significantlyhigher and albumin was significantly lower in the deceased patients.Conclusion: The presence of chronic kidney disease, low left ventricular EF, high pulmonary artery pressure, high CRP levels, increasedCRP/albumin ratio and high uric acid levels preceding TAVI may be helpful to determine the risk of mortality after the TAVI procedure.

🔬Design:Research Article

📍Scope:2015 Verileri

⚙️Variables:Domain Parameters

Abstract

Aim: Transcatheter aortic valve implantation has been used widely as an alternative treatment method for patients with symptomaticaortic stenosis carrying high surgical risk. Despite technological advances and increased experience, its early and late mortality rateis still relatively high and it is important to predict upcoming cardiac events and mortality for the management of patients. In thisstudy, we aimed to investigate the clinical and laboratory parameters affecting mortality after these procedures performed in ourclinic.Material and Methods: The patients who underwent TAVI due to severe AS between May 2015 and March 2019 were investigatedretrospectively. Demographic, echocardiographic and laboratory data of all patients were recorded. During the follow-up period(mean: 556 days), patients were divided into 2 groups; deceased patients (group 1, n=13) and living patients (group 2, n=34). Thedata of the patients before TAVI procedure were compared between the two groups.Results: Among demograhic data, the ratio of chronic kidney disease was significantly higher in the deceased group. Among echoparameters, left ventricular ejection fraction was significantly lower and pulmonary artery pressure was significantly higher in thedeceased group. Of laboratory parameters, blood urea nitrogen and creatinine levels were significantly higher and toral protein levelswere significantly lower in the deceased group. Additionally, leukocyte, uric acid, CRP and CRP/albumin ratio were significantlyhigher and albumin was significantly lower in the deceased patients.Conclusion: The presence of chronic kidney disease, low left ventricular EF, high pulmonary artery pressure, high CRP levels, increasedCRP/albumin ratio and high uric acid levels preceding TAVI may be helpful to determine the risk of mortality after the TAVI procedure.

🔖

Cite This Article

AKSU, E., SÖKMEN, A., SÖKMEN, G., ÇELİK, E., GÜNEŞ, H., ÖZGÜL, S., AYKAN, A. Ç., BALCIOĞLU, A. S. (2022). Predictors of mortality after transcatheter aortic valve implantation. Annals of Medical Research, Cilt: 27 - Sayı: 8, 2014–2021. https://ajindex.com/articles/446860

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (14)

Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population- based study. Lancet 2006;368:1005-11
Osnabrugge RL, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a metaanalysis and modeling study. J. Am. Coll. Cardiol 2013;62:1002-12
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-20
Holmes DR Jr, Brennan JM, Rumsfeld JS, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA 2015;313:1019-28
Ruparelia N, Panoulas VF, Frame A, et al. Impact of clinical and procedural factors upon C reactive protein dynamics following transcatheter aortic valve implantation World J Cardiol 2016;26;8:425-31
Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597–607
Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation 2011;123:299-308
Rodés-Cabau J, Webb JG, Cheung A, et al. Longterm outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience J Am Coll Cardiol 2012;60:1864–75
Michael JR, David H Adams, Neal S. Kleiman, et al. 2-Year outcomes in patient undergoing surgical or self-expanding transcatheter aortic valve replacement. JACC 2015;66:113-21
Dönmez Y, Örsan DU, Kurt İH. T wave positivity in lead aVR is associated with mortality after transcatheter aortic valve implantation. Arch Med Sci Atheroscler Dis 2019;e55-e62
Rheude T, Pellegrini C, Michel J, et al. Prognostic impact of anemia and iron-deficiency anemia in a contemporary cohort of patients undergoing transcatheter aortic valve implantation. Int J Cardiol 2017;244:93-9
Gotzmann M, Pljakic A, Bojara W, et al. Transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis-predictors of mortality and poor treatment response. Am Heart J 2011;162:238-45
Buja P, Napodano M, Ta